EvommuneEVMN
紐約證券 · USD
14.11
+0.32
(+2.32%)
收盤 08/27 03:59 (UTC+8)
盤後
13.90
13.90
(-1.49%)
08/27 03:59 (UTC+8)
EvommuneEVMN
14.11
+0.32
(+2.32%)
財務數據
損益表
- 0.05
- -
- -
- 0.10
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- 營業收入(億)
- 季增長率(%)
單位：美元千元
2026/Q2 | 2026/Q1 | 2025/Q4 | 2025/Q3 | 2024/Q4 | 2024/Q3 | 2023/Q4 | |
營業收入淨額 | - | - | - | 10,000 | - | - | 5,000 |
營業成本 | - | - | - | - | - | - | - |
營業毛利 | - | - | - | 10,000 | - | - | 5,000 |
營業費用 | 34,895 | 23,954 | 29,716 | 23,329 | 21,454 | 16,517 | 42,850 |
研發費用 | 26,412 | 17,319 | 20,403 | 19,639 | 17,831 | 13,289 | 31,997 |
推銷及管理費用 | 8,483 | 6,635 | 9,313 | 3,690 | 3,623 | 3,228 | 10,853 |
非經常性項目費用 | - | - | - | - | - | - | - |
其他營業費用 | - | - | - | - | - | - | - |
營業利益 | -34,895 | -23,954 | -29,716 | -13,329 | -21,454 | -16,517 | -37,850 |
其他收入及費用 | 2,649 | 2,280 | 1,443 | 854 | - | - | 3,797 |
利息費用 | - | - | - | - | - | - | - |
稅前純益 | -32,246 | -21,674 | -28,273 | -12,475 | -20,726 | -15,916 | -34,053 |
所得稅 | - | - | - | - | - | - | - |
稅後純益 | -32,246 | -21,674 | -28,273 | -12,475 | -20,726 | -15,916 | -34,053 |
基本每股稅後盈餘(元) | -0.89 | -0.64 | -1.43 | -0.41 | - | -0.99 | - |
稀釋每股稅後盈餘(元) | -0.90 | -0.64 | 15.14 | -8.07 | - | -0.99 | - |
基本平均股數(千股) | 36135.00 | 33670.00 | 19775.00 | 30077.00 | - | 16000.00 | - |
稀釋平均股數(千股) | 36135.00 | 33670.00 | 19775.00 | 30077.00 | - | 16000.00 | - |
還原基本每股稅後盈餘(元) | -0.89 | -0.64 | -1.43 | -0.41 | - | -0.99 | - |
還原稀釋每股稅後盈餘(元) | -0.90 | -0.64 | 15.14 | -8.07 | - | -0.99 | - |
還原基本平均股數(千股) | 36,135 | 33,670 | 19,775 | 30,077 | - | 16,000 | - |
還原稀釋平均股數(千股) | 36,135 | 33,670 | 19,775 | 30,077 | - | 16,000 | - |
EBITDA(千元) | -32,450 | -22,117 | -28,532 | -12,675 | -20,366 | -15,585 | -34,798 |